ITCA 650 (exenatide; Intarcia Therapeutics/Servier) is a drug-device combination currently being investigated in Phase III trials for the treatment of type 2 diabetes. The drug is subdermally implanted and utilizes the DUROS delivery device to continuously deliver the glucagon-like peptide-1 (GLP-1) agonist exenatide over an extended period of time. The DUROS device is a small, 4mm x 45mm subcutaneous osmotic mini-pump, designed to be replaced every six months to one year. ITCA 650 has demonstrated similar efficacy to injected GLP-1 agonists.
Exenatide is a member of the GLP-1 agonist class. GLP-1 agonists are incretin mimetics, mimicking the endogenous gut hormone GLP-1 which stimulates insulin-secreting beta cells in the pancreas. This triggers glucose-dependent insulin secretion, suppressing glucagon secretion, and thereby decreases plasma glucose levels. The major advantage of this class is the associated weight loss, as obesity is a common co-morbidity among type 2 diabetes patients. GLP-1 agonists also delay gastric emptying, thus increasing satiety and suppressing appetite.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 ITCA 650 : Diabetes type 2
LIST OF FIGURES 8 Figure 2: Datamonitor Healthcare’s drug assessment summary of ITCA 650 for type 2 diabetes
9 Figure 3: Datamonitor Healthcare’s drug assessment summary of ITCA 650 for type 2 diabetes
LIST OF TABLES 5 Table 1: ITCA 650 drug profile
6 Table 2: ITCA 650 Phase III data in type 2 diabetes
13 Table 3: ITCA 650 sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.